|Organization Name||National Jewish Health|
|Institutional ID Number||10-08|
|Technology Tags or Keywords|
All species of the genus Listeria secrete a major extracellular protein called p60. The laboratory of Dr. Lenz at National Jewish Health has purified the wildtype p60 protein and created a mutant form of p60 that lacks endopeptidase activity. They found that both forms of p60 contribute to the activation of dendritic cells (DC) in a manner that permits the activation of naïve NK cells. The enzymatically-null mutant p60 protein lacks the potential “off-target” effects, thus is an improvement over the wildtype p60 protein.
Treatment of diseases that will benefit from NK cells activation:
Investigators at NJH have identified a region of the p60 protein that is necessary and sufficient to elicit NK cell activation. Small polypeptides that contain this region retain functionality and can be used in animals. Modified versions of these polypeptides may show increase stability (and thus activity).
|Technology page URL||http://www.nationaljewish.org/research/Tech-Transfer/techsum10-08/|
|Detailed Technology Description||
Natural killer cells (or NK cells) are a type of cytotoxic lymphocyte that constitutes a major component of the innate immune system. NK cells play a major role in the rejection of tumors and cells infected by viruses. They kill cells by releasing small cytoplasmic granules of proteins called perforin and granzyme that cause the target cell to die by apoptosis (programmed cell death). Stimulation of NK cells can be used to treat infections and tumors, to improve adaptive immune responses to these agents and vaccines, and possibly to promote successful full-term pregnancy.
|TTO homepage URL||http://www.nationaljewish.org/research/Tech-Transfer/|
|URL to link to documents, images, videos, etc.||http://www.nationaljewish.org/research/Tech-Transfer/techsum10-08/|